Ohtuvayre (ensifentrine) is a prescription drug used to treat chronic obstructive pulmonary disease (COPD) in adults. Ohtuvayre comes as a liquid suspension for use with a nebulizer. To learn more ...
Please provide your email address to receive an email when new articles are posted on . The FDA based ensifentrine’s/Ohtuvayre’s approval on data from the phase 3 ...
The Food and Drug Administration (FDA) has approved Ohtuvayre ™ (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Study participants were ...
People living with chronic obstructive pulmonary disease (COPD) typically rely on maintenance inhalers to manage their daily symptoms. They may also take rescue inhalers for sudden breathing ...
Merck has reached a $10 billion deal to acquire Verona Pharma, a biotech whose first-in-class drug is already commercialized in one prevalent lung disorder and is showing promise in other respiratory ...
Verona Pharma is off to a promising start as it launches its first product, Ohtuvayre, a maintenance treatment for chronic obstructive pulmonary disorder (COPD). In 2024, Ohtuvayre generated sales of ...
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases Through this acquisition Merck will add ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results